Terms: = Breast cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
286 results:
1. Decoding the Versatile Landscape of Autophagic Protein VMP1 in cancer: A Comprehensive Review across Tissue Types and Regulatory Mechanisms.
Renna FJ; Gonzalez CD; Vaccaro MI
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612567
[TBL] [Abstract] [Full Text] [Related]
2. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
3. Withaferin A alters the expression of microRNAs 146a-5p and 34a-5p and associated hub genes in MDA-MB-231 cells.
Shuaib M; Chaudhri S; Kumar S
Biomol Concepts; 2024 Jan; 15(1):. PubMed ID: 38525814
[TBL] [Abstract] [Full Text] [Related]
4. Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer.
Singh S; Saxena S; Sharma H; Paudel KR; Chakraborty A; MacLoughlin R; Oliver BG; Gupta G; Negi P; Singh SK; Dua K
Pathol Res Pract; 2024 Apr; 256():155222. PubMed ID: 38452582
[TBL] [Abstract] [Full Text] [Related]
5. HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer.
He Y; Ma Y; Zhu Y; Zhang J; Zhao S; Zhang D; Xu D; Li Y; Tong Z; Zhao W
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38214343
[TBL] [Abstract] [Full Text] [Related]
6. The dual activity of CaONPs as a cancer treatment substance and at the same time resistance to harmful microbes.
Awaad A; Olama ZA; El-Subruiti GM; Ali SM
Sci Rep; 2023 Dec; 13(1):22940. PubMed ID: 38135693
[TBL] [Abstract] [Full Text] [Related]
7. Individual participant data from digital sources informed and improved precision in the evaluation of predictive biomarkers in Bayesian network meta-analysis.
Umemneku-Chikere CM; Wheaton L; Poad H; Ray D; Andrade IC; Khan S; Tappenden P; Abrams KR; Owen RK; Bujkiewicz S
J Clin Epidemiol; 2023 Dec; 164():96-103. PubMed ID: 37918640
[TBL] [Abstract] [Full Text] [Related]
8. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic cancer Guides Rational Therapies.
Hasselluhn MC; Schlösser D; Versemann L; Schmidt GE; Ulisse M; Oschwald J; Zhang Z; Hamdan F; Xiao H; Kopp W; Spitalieri J; Kellner C; Schneider C; Reutlinger K; Nagarajan S; Steuber B; Sastra SA; Palermo CF; Appelhans J; Bohnenberger H; Todorovic J; Kostyuchek I; Ströbel P; Bockelmann A; König A; Ammer-Herrmenau C; Schmidleitner L; Kaulfuß S; Wollnik B; Hahn SA; Neesse A; Singh SK; Bastians H; Reichert M; Sax U; Olive KP; Johnsen SA; Schneider G; Ellenrieder V; Hessmann E
Gastroenterology; 2024 Feb; 166(2):298-312.e14. PubMed ID: 37913894
[TBL] [Abstract] [Full Text] [Related]
9. Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy.
Geerinckx B; Teuwen LA; Foo T; Vandamme T; Smith A; Peeters M; Price T
Expert Rev Anticancer Ther; 2023; 23(12):1237-1249. PubMed ID: 37842857
[TBL] [Abstract] [Full Text] [Related]
10. Mutation Profile via Next-Generation Sequencing in Patients with Colorectal Adenocarcinoma and Its Clinicopathological Correlation.
Osman S; Kahraman Çetin N; Erdoğdu İH; Meteoğlu İ
Turk J Gastroenterol; 2023 Nov; 34(11):1124-1133. PubMed ID: 37737217
[TBL] [Abstract] [Full Text] [Related]
11. Mesonephric-like adenocarcinoma of the female genital tract: possible role of kras-targeted treatment-detailed molecular analysis of a case series and review of the literature for targetable somatic kras-mutations.
Brambs CE; Horn LC; Hiller R; Krücken I; Braun C; Christmann C; Monecke A; Höhn AK
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15727-15736. PubMed ID: 37668797
[TBL] [Abstract] [Full Text] [Related]
12. A potential tumor marker: Chaperonin containing TCP‑1 controls the development of malignant tumors (Review).
Zheng L; Chen X; Zhang L; Qin N; An J; Zhu J; Jin H; Tuo B
Int J Oncol; 2023 Sep; 63(3):. PubMed ID: 37539774
[TBL] [Abstract] [Full Text] [Related]
13. RAS‑stimulated release of exosomal
Kim O; Tran PT; Gal M; Lee SJ; Na SH; Hwangbo C; Lee JH
Int J Mol Med; 2023 Sep; 52(3):. PubMed ID: 37503759
[TBL] [Abstract] [Full Text] [Related]
14. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or kras mutation.
Piha-Paul SA; Tseng C; Tran HT; Gao M; Karp DD; Subbiah V; Tsimberidou AM; Kawedia JD; Fu S; Pant S; Yap TA; Morris VK; Kee BK; Blum Murphy M; Lim J; Meric-Bernstam F
Cancer Chemother Pharmacol; 2023 Aug; 92(2):107-118. PubMed ID: 37314501
[TBL] [Abstract] [Full Text] [Related]
15. Effect of Smilax spp. and Phellinus linteus combination on cytotoxicity and cell proliferation of breast cancer cells.
Chalertpet K; Sangkheereeput T; Somjit P; Bankeeree W; Yanatatsaneejit P
BMC Complement Med Ther; 2023 Jun; 23(1):177. PubMed ID: 37264344
[TBL] [Abstract] [Full Text] [Related]
16. Results from an IFCC global survey on laboratory practices for the analysis of circulating tumor DNA.
Linder MW; Huggett JF; Baluchova K; Capoluongo ED; Payne DA; Salinas AV; Haselmann V; Ashavaid T; Pan S; Ahmad-Nejad P;
Clin Chim Acta; 2023 Jul; 547():117398. PubMed ID: 37217114
[TBL] [Abstract] [Full Text] [Related]
17. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
Zhou T; Xie Y; Hou X; Bai W; Li X; Liu Z; Man Q; Sun J; Fu D; Yan J; Zhang Z; Wang Y; Wang H; Jiang W; Gao S; Zhao T; Chang A; Wang X; Sun H; Zhang X; Yang S; Huang C; Hao J; Liu J
J Exp Clin Cancer Res; 2023 May; 42(1):111. PubMed ID: 37143164
[TBL] [Abstract] [Full Text] [Related]
18. Identification of circulating tumour DNA (ctDNA) from the liquid biopsy results: Findings from an observational cohort study.
Myint KZY; Shimabuku M; Horio R; Kaneda M; Shimizu Y; Taguchi J
Cancer Treat Res Commun; 2023; 35():100701. PubMed ID: 37094468
[TBL] [Abstract] [Full Text] [Related]
19. High expression of the RET receptor tyrosine kinase and its ligand GDNF identifies a high-risk subset of estrogen receptor positive breast cancer.
Kakati RT; Kim H; Whitman A; Spanheimer PM
Breast Cancer Res Treat; 2023 Jun; 199(3):589-601. PubMed ID: 37061618
[TBL] [Abstract] [Full Text] [Related]
20. Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines.
Tawfeeq N; Lazarte JMS; Jin Y; Gregory MD; Lamango NS
Oncotarget; 2023 Mar; 14():243-257. PubMed ID: 36961909
[TBL] [Abstract] [Full Text] [Related]
[Next]
